nCOVID-19
10y
Better.Be.First.
Fast patient
Proof of concept trials

PROOF OF CONCEPT TRIALS

proof of concept trials

ARENSIA delivers high degree of scientific and logistical expertise for Phase I/Ib/IIa and PROOF OF CONCEPT patient studies.

MORE

PHASE I SPECIAL POPULATIONS

phase i special populations

ARENSIA offers exceptional fast recruitment rates for renal and hepatic impaired patients.

MORE

REGULATORY PROCESS

regulatory process

ARENSIA has the know-how to successfully manage the regulatory process in various Eastern European countries.

MORE

ARENSIA begins Clinical Trial Program to test DIFFUSION’s lead drug for the treatment of hospitalized COVID-19 patients

HOME · NEWS · ARENSIA BEGINS CLINICAL TRIAL PROGRAM TO TEST DIFFUSION’S LEAD DRUG FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS

We at ARENSIA are proud to announce today that we have entered into an agreement with Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) to begin a clinical trial program to test Diffusion’s lead drug trans sodium crocetinate (TSC) for the treatment of hospitalized COVID-19 patients presenting with lowered blood oxygen levels, a condition known as hypoxemia.

The trial will be performed at the National Institute of Infectious Diseases “Prof. Dr. Matei Bals” (NIID) in Bucharest, Romania, where ARENSIA conducts the most complex exploratory clinical trials on a wide range of infectious diseases in advanced specialist Phase I facilities. Noted infectious disease researcher Prof. Adrian Streinu-Cercel, M.D., Ph.D., General Manager of the NIID, will serve as Principal Investigator.

We will valiantly overcome any obstacles in the way of this program, as this is our contribution to overcoming the pandemic and saving countless human lives!

Below, please find Diffusion Pharmaceutical’s press release:

https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases/default.aspx

21.05.2020
VIDEO INTRO

We use technologies, such as cookies, and process personal data, such as IP addresses and cookie identifiers, to personalise content based on your interests, measure the performance of our content, and derive insights about the audiences who saw it. You can read more about our Cookie Policy here.

I accept I refuse